

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 5TH BOARD MEETING FOR FY2025

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 1 August 2025, the Company issued a notice of Board meeting to its directors (the “**Directors**”) convening the 5th Board meeting for the financial year ending 31 December 2025 (“**FY2025**”). The meeting was duly convened on 13 August 2025 via a combination of a physical meeting and teleconference, with the full Board of nine (9) Directors in attendance. The said meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed:

1. That the full text and summary of the half yearly financial statement for FY2025 prepared in accordance with the accounting standards of the People's Republic of China (the “**PRC**”), and the interim financial report for FY2025 prepared in accordance with the International Financial Reporting Standards, be approved.

To the best of the knowledge of the Directors and management of the Company, there is no other information that would cause the contents of the aforesaid financial statements to be false or misleading.

Further information is set out in the Company's separate announcement on its second quarter and/or half-year results released on the same date as this announcement.

2. That the half-yearly “Report on the Deposit of Proceeds and the Use of Proceeds (募集资金存放与实际使用情况的专项报告)” for FY2025 be approved.

Further information is set out in the Company's announcement titled “*Update on the Deposit of Net Proceeds and the Use of New Proceeds*” released on the same date as this announcement.

3. That the proposed contents of the “Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司)” be approved.

Further information is set out in the Company's announcement titled “*Update Announcement on Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd.*” released on the same date as this announcement.

4. That the proposed purchase of liability insurance for the Company and its Directors, supervisors and senior management be approved for submission to shareholders for consideration and approval at a general meeting of the Company to be convened in due course.

To further enhance the Company's corporate governance and risk management system, facilitate the due exercise of powers and the effective discharge of duties by the Company's Directors, supervisors and senior management, foster a sound environment for the sustainable development of the Company, and safeguard the legitimate rights and interests of the Company and its shareholders, the Company proposes to purchase liability insurance (the "**Liability Insurance**") for the Company and all of its Directors, supervisors and senior management (the "**Proposed Purchase of Liability Insurance**") in accordance with applicable laws, regulations and rules, including the *Company Law of the PRC* (《中华人民共和国公司法》), the *Code of Corporate Governance of Listed Companies* (《上市公司治理准则》) issued by the China Securities Regulatory Commission (中国证券监督管理委员会).

In order to improve decision-making efficiency, the Board proposes to seek shareholders' approval to authorise the management of the Company to handle all matters relating to the purchase of the Liability Insurance within the framework of the proposed insurance plan. Such matters include, but are not limited to, selecting the insurance provider, determining the insured liability limit, negotiating the insurance terms, executing the relevant legal documents, attending to other matters in connection with the purchase of the Liability Insurance, as well as arranging its renewal or re-purchase upon or prior to the expiry of the insurance contract.

As all the Directors will be insured under the Liability Insurance and are therefore regarded as interested in the Proposed Purchase of Liability Insurance, they have abstained from voting on this resolution. The Board resolved that this resolution be approved for submission to shareholders for consideration and approval at a general meeting of the Company to be convened in due course.

Further information is set out in the Company's announcement titled "*Proposed Purchase of Liability Insurance for the Company and its Directors, Supervisors and Senior Management*" released on the same date as this announcement.

5. That the proposed amendments to the existing shareholders' mandate for interested person transactions be approved.

Further information will be set out in a circular to shareholders of the Company to be issued in due course.

Mr. Guo Min, Ms. Wang Lei, Mr. Xing Jianhua, and Ms. Mao Weiwen, being interested Directors, abstained from voting on this resolution.

The resolutions referred to in paragraphs 4 and 5 above will be tabled for shareholders' approval at a general meeting of the Company to be convened in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 August 2025